July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Best Disease is a Phenocopy of North Carolina Macular Dystrophy (NCMD / MCDR1)
Author Affiliations & Notes
  • Kent W Small
    Molecular Insight Research Foundation, Glendale and Los Angeles, California, United States
    Macula and Retina Institute, Glendale and Los Angeles, California, United States
  • Benjamin Bakall
    University of Arizona College of Medicine, Phoenix, Arizona, United States
  • Edwin M Stone
    University of Iowa, Iowa City, Iowa, United States
  • Robert Wiggins
    Asheville Eye Associates, North Carolina, United States
  • Nitin Udar
    Molecular Insight Research Foundation, Glendale and Los Angeles, California, United States
    Macula and Retina Institute, Glendale and Los Angeles, California, United States
  • Steven Agemy
    SUNY Downstate Medical Center University, Brooklyn, New York, United States
  • Fadi Shaya
    Molecular Insight Research Foundation, Glendale and Los Angeles, California, United States
    Macula and Retina Institute, Glendale and Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Kent Small, None; Benjamin Bakall, None; Edwin Stone, None; Robert Wiggins, None; Nitin Udar, None; Steven Agemy, None; Fadi Shaya, None
  • Footnotes
    Support  FFB Grant # BR-GE-1216-0715-CSH
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5041. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kent W Small, Benjamin Bakall, Edwin M Stone, Robert Wiggins, Nitin Udar, Steven Agemy, Fadi Shaya; Best Disease is a Phenocopy of North Carolina Macular Dystrophy (NCMD / MCDR1). Invest. Ophthalmol. Vis. Sci. 2019;60(9):5041.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : North Carolina Macular Dystrophy (NCMD / MCDR1) and Best disease are both autosomal dominant macular dystrophies. While both have phenotypic variability, NCMD has considerably more. NCMD has three grades of severity which are present from birth. NCMD grade 1 is drusen, grade 2 is confluent drusen and / or small fibrosis and CNVM, grade 3 is a developmental defect (coloboma like) in the central macula. Isolated individuals outside the context of other affected family members can be difficult to accurately diagnose and differentiate the two disease intities. We will perform a case series evaluation of the similarities and differences between Best disease and NCMD grade 2.

Methods : Clinical findings including fundus photography and OCTs were evaluated in 5 individuals with NCMD grade 2 and two with Best disease. EOG was performed in one NCMD subject. Sanger DNA sequencing was performed to confirm diagnoses. IRB approval was obtained.

Results : Five of NCMD grade 2 individuals have clinical findings indistinguishable from Best's macular dystrophy. One NCMD subject had an abnormal EOG with a normal ERG, which has previously been considered a unique feature of NCMD. OCT in Best disease can demonstrate a lucency deep to the elevated vitelliform lesion which is not seen in NCMD. One NCMD grade 2 subject had had elevated submacular fluid giving a pseudo-vitelliform appareance on OCT.

Conclusions : Best disease is another phenocopy of NCMD. There is considerable clincial overlap between NCMD and Best macualr dystrophy. Like Best disease, NCMD can also have a normal EOG with a normal ERG. Examining other family members can help differentiate the two. DNA sequencing can provide a more definitivve molecular diagnosis.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×